The CooperCOO -0.20%89 EBIT per Share is $2.55 as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $100.88 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 690 Medical Devices & Instruments companies, The Cooper ranks better than 51.01% on this metric.
The Cooper's EBIT per Share for the
three
months ended in Apr. 2026 was $-0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $2.55.
During the past 12 months, the average EBIT per Share Growth Rate of The Cooper was -33.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 10.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for The Cooper's EBIT per Share or its related term are showing as below:
COO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -27.4 Med: 14.3 Max: 49.1
Current: 10.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of The Cooper was 49.10% per year. The lowest was -27.40% per year. And the median was 14.30% per year.
COO's 3-Year EBIT Growth Rate is ranked better than 51.01% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs COO: 10.20
The Cooper's EBIT for the
three
months ended in Apr. 2026 was $-28 Mil.
The Cooper (NAS:COO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
The Cooper EBIT per Share Related Terms
The Cooper EBIT per Share Historical Data
* Premium members only.
The historical data trend for The Cooper's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a EBIT per Share of $2.55 as of Apr. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #338 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 49%.
Is The Cooper's EBIT per Share too high?
The Cooper's current EBIT per Share is $2.55. The Medical Devices & Instruments industry median EBIT per Share is 9.60. The Cooper's value of $2.55 is 73.4% below this industry median. Based on the distribution chart, The Cooper ranks #338 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's EBIT per Share compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #338 out of 690 companies for EBIT per Share. This puts The Cooper in the upper half of its industry. The industry median EBIT per Share is 9.60. The Cooper's value of $2.55 is 73.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current EBIT per Share of $2.55 is 73.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current EBIT per Share is $2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.88, compared to a current price of $70.88 — trading 29.7% below its estimated fair value. The current EBIT per Share is $2.55 and 73.4% below the Medical Devices & Instruments industry median of 9.60. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For The Cooper (COO), the current EBIT per Share is $2.55 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $70.88 is trading 29.7% below its estimated GF Value™ of $100.88.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
EBIT per Share: $2.55
GF Value™: $100.88 vs. price of $70.88 (29.7% below fair value)
Industry Position: 73.4% below the Medical Devices & Instruments median (#338 of 690)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
